Population Pharmacokinetic Modeling of Thymoglobulin in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival

This is the authors' abstract. We don't add key points for this paper.

To prevent graft versus host disease (GvHD) and rejection in hematopoietic cell transplantation (HCT), children receive anti-thymocyte globulin (ATG), a polyclonal antibody depleting T-cells, as part of the conditioning regimen. The therapeutic window is critical as over-exposure may result in delayed reconstitution of donor T-cells and increased risk of viral infections. Our objective is to describe the population pharmacokinetics (PK) of Thymoglobulin as a first step towards an evidence based dosing regimen of Thymoglobulin for HCT in children.